- Home
- NIVF vs HSDT Comparison
NIVF vs HSDT Comparison
Compare NIVF & HSDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NIVF
- HSDT
- Stock Information
- Founded
- NIVF 2011
- HSDT N/A
- Country
- NIVF Thailand
- HSDT United States
- Employees
- NIVF N/A
- HSDT N/A
- Industry
- NIVF
- HSDT Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- NIVF
- HSDT Health Care
- Exchange
- NIVF NYSE
- HSDT Nasdaq
- Market Cap
- NIVF 2.1M
- HSDT 2.5M
- IPO Year
- NIVF N/A
- HSDT N/A
- Fundamental
- Price
- NIVF $0.62
- HSDT $8.05
- Analyst Decision
- NIVF
- HSDT Hold
- Analyst Count
- NIVF 0
- HSDT 1
- Target Price
- NIVF N/A
- HSDT N/A
- AVG Volume (30 Days)
- NIVF 3.8M
- HSDT 235.6K
- Earning Date
- NIVF 01-01-0001
- HSDT 08-11-2025
- Dividend Yield
- NIVF N/A
- HSDT N/A
- EPS Growth
- NIVF N/A
- HSDT N/A
- EPS
- NIVF N/A
- HSDT N/A
- Revenue
- NIVF $5,433,375.00
- HSDT $434,000.00
- Revenue This Year
- NIVF N/A
- HSDT N/A
- Revenue Next Year
- NIVF N/A
- HSDT $75.13
- P/E Ratio
- NIVF N/A
- HSDT N/A
- Revenue Growth
- NIVF 5.79
- HSDT N/A
- 52 Week Low
- NIVF $0.61
- HSDT $8.00
- 52 Week High
- NIVF $656.00
- HSDT $1,200.00
- Technical
- Relative Strength Index (RSI)
- NIVF 27.45
- HSDT 21.35
- Support Level
- NIVF $0.61
- HSDT $8.21
- Resistance Level
- NIVF $1.24
- HSDT $10.70
- Average True Range (ATR)
- NIVF 0.12
- HSDT 1.47
- MACD
- NIVF 0.03
- HSDT 6.62
- Stochastic Oscillator
- NIVF 2.36
- HSDT 0.45
About NIVF NEWGENIVF GROUP LIMITED
NewGenIvf Group Ltd is a company engaged in providing assisted reproductive services in Asia Pacific with a focus on providing fertility treatments to fulfil the dreams of building families, NewGenIvf mainly offers two services, namely first which is a in-vitro fertilization (IVF) treatment service, comprising traditional IVF and egg donation; and surrogacy and ancillary caring services.
About HSDT Helius Medical Technologies Inc. (DE)
Helius Medical Technologies Inc is a neurotech company focused on neurological wellness. The company's purpose is to develop, license, or acquire non-invasive technologies targeted at reducing symptoms of neurological disease or trauma. The company's product, known as the Portable Neuromodulation Stimulator (PoNS) is authorized for sale in Canada as a class II, a non-implantable medical device intended for use as a short-term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury and is to be used in conjunction with supervised therapeutic exercise.